GoAI
Get started
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$26.72

−$0.33 · -1.22%

Aug 21, 4:00 PM ET

NRIX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

33

Expensive

Momentum

68

Gaining

Sentiment

72

Bullish

Risk resilience

48

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Arthur T. Sands
Listed since
Jul 24, 2020
Employees
317

Market position

Day range

Current $26.72

52-week range

Current $26.72

Open
$27.175
Previous close
$27.05
Volume
1.49M
0.87× average
Average volume
1.7M
Average daily volume
Market cap
2.77B USD
Beta
1.79
Market reference 1
50-day average
$23.2826
+14.76% above average
200-day average
$18.2195
+46.66% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.27B USD
EV / EBITDA
-5.2×
Earnings yield
-18.05%
Free cash flow yield
-17.98%

Profitability & efficiency

Return on equity
-49.09%
Return on assets
-38.43%
Return on invested capital
-47.26%

Financial health

Current ratio
7.02×
Altman Z-score
8.26
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends133%-89%-310%-531%Gross margin, FY2021: -291.37%Gross margin, FY2022: -377.64%Gross margin, FY2023: -145.69%Gross margin, FY2024: -306.30%Gross margin, FY2025: 77.55%Operating margin, FY2021: -396.26%Operating margin, FY2022: -476.01%Operating margin, FY2023: -201.41%Operating margin, FY2024: -390.52%Operating margin, FY2025: -340.16%Net margin, FY2021: -393.93%Net margin, FY2022: -466.93%Net margin, FY2023: -186.98%Net margin, FY2024: -354.85%Net margin, FY2025: -314.90%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -291.37%. Gross margin FY2022 -377.64%. Gross margin FY2023 -145.69%. Gross margin FY2024 -306.30%. Gross margin FY2025 77.55%. Operating margin FY2021 -396.26%. Operating margin FY2022 -476.01%. Operating margin FY2023 -201.41%. Operating margin FY2024 -390.52%. Operating margin FY2025 -340.16%. Net margin FY2021 -393.93%. Net margin FY2022 -466.93%. Net margin FY2023 -186.98%. Net margin FY2024 -354.85%. Net margin FY2025 -314.90%.

Income trends

Revenue

83.98M USD+53.95%

Operating income

−285.67M USD-34.10%

Net income

−264.46M USD-36.62%
Income trends across reported periods120.94M USD−26.91M USD−174.77M USD−322.63M USDRevenue, FY2021: 29.75M USDRevenue, FY2022: 38.63M USDRevenue, FY2023: 76.99M USDRevenue, FY2024: 54.55M USDRevenue, FY2025: 83.98M USDOperating income, FY2021: −117.89M USDOperating income, FY2022: −183.87M USDOperating income, FY2023: −155.06M USDOperating income, FY2024: −213.03M USDOperating income, FY2025: −285.67M USDNet income, FY2021: −117.19M USDNet income, FY2022: −180.36M USDNet income, FY2023: −143.95M USDNet income, FY2024: −193.57M USDNet income, FY2025: −264.46M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 29.75M USD. Revenue FY2022 38.63M USD. Revenue FY2023 76.99M USD. Revenue FY2024 54.55M USD. Revenue FY2025 83.98M USD. Operating income FY2021 −117.89M USD. Operating income FY2022 −183.87M USD. Operating income FY2023 −155.06M USD. Operating income FY2024 −213.03M USD. Operating income FY2025 −285.67M USD. Net income FY2021 −117.19M USD. Net income FY2022 −180.36M USD. Net income FY2023 −143.95M USD. Net income FY2024 −193.57M USD. Net income FY2025 −264.46M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue83.98M USD54.55M USD76.99M USD38.63M USD29.75M USD
Cost of goods sold18.86M USD221.63M USD189.15M USD184.5M USD116.43M USD
Gross profit65.12M USD−167.08M USD−112.16M USD−145.87M USD−86.68M USD
Research and development308.16M USD221.63M USD189.15M USD184.5M USD116.43M USD
Selling, general, and administrative52.74M USD45.94M USD42.9M USD38M USD31.2M USD
Operating expenses350.79M USD45.94M USD42.9M USD38M USD31.2M USD
Interest income21.97M USD19.73M USD11.12M USD3.51M USD823K USD
Depreciation and amortization18.86M USD8.02M USD6.13M USD4.15M USD1.99M USD
Operating income−285.67M USD−213.03M USD−155.06M USD−183.87M USD−117.89M USD
Net income−264.46M USD−193.57M USD−143.95M USD−180.36M USD−117.19M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$34.67

29.75% upside
Past 12 months12-month forecastHigh $45.00Average $34.67Low $28.00

Rating distribution

19 ratings
Strong buy00%
Buy19100%
Hold00%
Sell00%
Strong sell00%

NRIX news

globenewswire.com

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and…

Read source
defenseworld.net

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $33.00 to $36.00. Royal Bank…

Read source
globenewswire.com

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive…

Read source
globenewswire.com

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor Phase 3 trial designed to demonstrate…

Read source
zacks.com

Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

Read source
globenewswire.com

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein…

Read source

NRIX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NRIX

research.disclaimer